Here we characterize the structure, stability and intracellular mode-of-action of DermaVir nanomedicine that is under clinical development for the treatment of HIV/AIDS. This nanomedicine is comprised of pathogen-like pDNA/PEIm nanoparticles (NPs) having the structure and function resembling spherical viruses that naturally evolved to deliver nucleic acids to the cells. Atomic force microscopy demonstrated spherical 100–200nm NPs with a smooth polymer surface protecting the pDNA in the core. Optical-absorption determined both the NP structural stability and biological activity relevant to their ability to escape from the endosome and release the pDNA at the nucleus. Salt, pH and temperature influence the nanomedicine shelf-life and intracellular stability. This approach facilitates the development of diverse polyplex nanomedicines where the delivered pDNA-expressed antigens induce immune responses to kill infected cells.

No abstract

The peptides Ac-His-Pro-His-Pro-His-NH(2) (L1) and Ac-Lys-His-Pro-His-Pro-His-Gln-NH(2) (L2) have been prepared and the equilibria of their proton, copper(II) and zinc(II) complexes in aqueous solution have been studied by the combination of pH-potentiometric titrations, UV/visible and circular dichroism (CD) spectroscopy. The latter methods also provided information on solution structure of the complexes formed under different conditions. Both ligands formed complexes with three imidazole nitrogens around the metal ion at pH ~7. In the L1 containing system precipitation of either copper(II) or zinc(II) complexes occurred upon slight increase of the pH. The re-titration of the filtered and acidified precipitates revealed that the insoluble materials were neutral complexes rather than metal-hydroxides. Indeed, by attaching amino acids with polar side-chains to the His-Pro-His-Pro-His template in L2 we could prevent any precipitation, and the soluble complexes around pH ~7 exerted three imidazole nitrogens and a (deprotonated) water molecule around the metal ions. To our knowledge L2 provides the first example of a short peptide preventing both the amide nitrogen coordination in copper(II) and the formation of copper(II) and zinc(II) hydroxides. The zinc(II) and copper(II) complexes at pH ~7 having similar structure to the natural hydrolytic and redox enzymes, respectively, showed considerable activity in hydrolytic cleavage assays with a model substrate (2-hydroxypropyl-4-nitrophenyl phosphate), as well as with native plasmid DNA, and in a superoxide dismutase-like reaction.

West Nile virus (WNV) is a mosquito-borne flavivirus that is endemic in Africa, the Middle East, Europe and the United States. There is currently no antiviral treatment or human vaccine available to treat or prevent WNV infection. DNA plasmid-based vaccines represent a new approach for controlling infectious diseases. In rodents, DNA vaccines have been shown to induce B cell and cytotoxic T cell responses and protect against a wide range of infections. In this study, we formulated a plasmid DNA vector expressing the ectodomain of the E-protein of WNV into nanoparticles by using linear polyethyleneimine (lPEI) covalently bound to mannose and examined the potential of this vaccine to protect against lethal WNV infection in mice. Mice were immunized twice (prime – boost regime) with the WNV DNA vaccine formulated with lPEI-mannose using different administration routes (intramuscular, intradermal and topical). In parallel a heterologous boost with purified recombinant WNV envelope (E) protein was evaluated. While no significant E-protein specific humoral response was generated after DNA immunization, protein boosting of DNA-primed mice resulted in a marked increase in total neutralizing antibody titer. In addition, E-specific IL-4 T-cell immune responses were detected by ELISPOT after protein boost and CD8+ specific IFN-γ expression was observed by flow cytometry. Challenge experiments using the heterologous immunization regime revealed protective immunity to homologous and virulent WNV infection.

There is no clinically available cancer immunotherapy that exploits Langerhans cells (LCs), the epidermal precursors of dendritic cells (DCs) that are the natural agent of antigen delivery. We developed a DNA formulation with a polymer and obtained synthetic 'pathogen-like' nanoparticles that preferentially targeted LCs in epidermal cultures. These nanoparticles applied topically under a patch-elicited robust immune responses in human subjects. To demonstrate the mechanism of action of this novel vaccination strategy in live animals, we assembled a high-resolution two-photon laser scanning-microscope. Nanoparticles applied on the native skin poorly penetrated and poorly induced LC motility. The combination of nanoparticle administration and skin treatment was essential both for efficient loading the vaccine into the epidermis and for potent activation of the LCs to migrate into the lymph nodes. LCs in the epidermis picked up nanoparticles and accumulated them in the nuclear region demonstrating an effective nuclear DNA delivery in vivo. Tissue distribution studies revealed that the majority of the DNA was targeted to the lymph nodes. Preclinical toxicity of the LC-targeting DNA vaccine was limited to mild and transient local erythema caused by the skin treatment. This novel, clinically proven LC-targeting DNA vaccine platform technology broadens the options on DC-targeting vaccines to generate therapeutic immunity against cancer.